Hubungan Antara Parameter Hematologi saat Perawatan Fase Induksi dengan Kejadian Demam Neutropenia pada Anak Leukemia Limfoblastik Akut
Sari
Latar belakang. Demam neutropenia yang terjadi, terutama fase induksi, merupakan keadaan yang mengancam jiwa serta membutuhkan penanganan yang cepat dan segera. Di RSUP Dr. Sardjito, tingkat mortalitas 11% dari 25% insiden demam neutropenia pada Leukemia Limfoblastik Akut (LLA) fase induksi. Parameter hematologi diduga berperan terhadap kejadian demam neutropenia pada anak LLA fase induksi.
Tujuan. Mengetahui hubungan antara parameter hematologi terhadap kejadian demam neutropenia anak LLA pada fase induksi.
Metode. Penelitian kasus-kontrol dengan besar sampel 100 anak. Penelitian dilakukan pada pasien yang sedang dan telah menjalani Indonesian Protocol Acute Lymphoblastic Leukemia (ALL) 2006 fase induksi, menderita demam neutropenia, dan berusia kurang dari 18 tahun. Sampel diambil secara konsekutif berdasarkan data rekam medik dan dilakukan matching berdasarkan usia, jenis kelamin, dan demam neutropenia yang terjadi pertama kali saat perawatan. Uji statistik dengan kai kuadrat dan analisis multivariat dengan regresi logistik.
Hasil. Secara statistik, hasil analisis multivariat menunjukkan monositopenia dengan jumlah monosit ≤100/mm3 dan merupakan satu-satunya variabel yang berkaitan dengan kejadian demam neutropenia, OR 3,570 (p=0,005;95%CI=1,466-8,695).
Kesimpulan. Monositopenia dengan jumlah monosit ≤100/mm3 berhubungan dengan kejadian demam neutropenia pada anak LLA fase induksi.
Kata Kunci
Teks Lengkap:
PDFReferensi
Lyman GH, Rolston K. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 2010;6:149-52.
Widjajanto PH, Supriyadi E, Purwanto I, Sutaryo S. Dexamethasone versus prednisone in childhood acute lymphoblastic leukemia treatment:results of the Indonesian randomized trial. unpublished 2012;92-108.
Widjajanto PH, Sutaryo S, Purwanto I, Ven PM, Veerman PJ. Early response to dexamethasone as prognostic factor: result from Indonesian childhood WK-ALL protocol in Yogyakarta. J Oncol 2012;2012:1-8.
Rondinelli PI, Ribeiro KC, de CB. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006;28:665-70.
Oguz A, Karadeniz C, Ckitak EC, Cil V. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol 2006;23:143-51.
Donadieu J, Auclerc MF, Baruchel A, Hill C. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE). Br J Cancer 2000;83:1617-22.
Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37.
Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005;23:7958-66.
Santolaya ME, Alvarez AM, Becker A, Zubieta M. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001;19:3415-21.
Eyrich M, Wiegering V , Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Br J Haematol 2009;147:360-70.
Klaassen RJ, Goodman TR, Pham B, Doyle JJ. “Low-risk†prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012-9.
Acha-Orbea H, Berg L; Cancro M, Zwickey H. Basic concepts in immunology. Dalam Murphy K, Travers P, dan Walport M, penyunting. Janeway’s immunobiology. New York: Garland Science;2008.h.1-27.
Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol 1999;22:103-5.
Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996;14:919-24.
Blay JY, Chauvin F, Le CA, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996;14:636-43.
Choi CW, Sung HJ, Park KH, Kim JS. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003;73:263-6.
Ray-Coquard I, Borg C, Bachelot T, Blay JY. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003;88:181-6.
Yetgin S, Cetin M. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia. Leuk.Lymphoma 2003;44:489-95.
Safdar A, Rodriguez GH, Lichtiger B, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006;106:2664-71.
DOI: http://dx.doi.org/10.14238/sp16.3.2014.183-8
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.